

10/796,313

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Jul 12 BEILSTEIN enhanced with new display and select options,
resulting in a closer connection to BABS
NEWS 4 AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display
fields
NEWS 5 AUG 02 CAPLUS and CA patent records enhanced with European and Japan
Patent Office Classifications
NEWS 6 AUG 02 The Analysis Edition of STN Express with Discover!
(Version 7.01 for Windows) now available
NEWS 7 AUG 27 BIOCOMMERCE: Changes and enhancements to content coverage
NEWS 8 AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added for legal
status data from INPADOC
NEWS 9 SEP 01 INPADOC: New family current-awareness alert (SDI) available
NEWS 10 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 11 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 12 SEP 27 STANDARDS will no longer be available on STN
NEWS 13 SEP 27 SWETSCAN will no longer be available on STN

NEWS EXPRESS JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:15:35 ON 20 OCT 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

10/796,313

FILE 'REGISTRY' ENTERED AT 18:15:50 ON 20 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 OCT 2004 HIGHEST RN 765878-56-6
DICTIONARY FILE UPDATES: 19 OCT 2004 HIGHEST RN 765878-56-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> e bicalutamide/cn


E1	1	BICALON/CN
E2	1	BICALPHOS/CN
E3	1 -->	BICALUTAMIDE/CN
E4	1	BICARBAMALDEHYDE/CN
E5	1	BICARBAMAMIC ACID/CN
E6	1	BICARBAMAMIDE/CN
E7	1	BICARBAMAMIDE, 2-(4-BIPHENYLYL)-N-METHYL-3-PHENYL-/CN
E8	1	BICARBAMAMIDINE/CN
E9	1	BICARBAMIC ACID/CN
E10	1	BICARBAMIC ACID (4-AMINO-3,5-XYLYL)-, DIETHYL ESTER/CN
E11	1	BICARBAMIC ACID, (((1-CARBOXY-2-HYDROXYETHYL) CARBAMOYL) METHYL)-, 1,4-DIBENZYL METHYL ESTER/CN
E12	1	BICARBAMIC ACID, (((CARBOXYMETHYL) CARBAMOYL) METHYL)-, DIBENZYL METHYL ESTER/CN

=> s e3

L1 1 BICALUTAMIDE/CN

=> d scan

L1 1 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI)
MF C18 H14 F4 N2 O4 S



10/796,313

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.27

5.48

FILE 'CAPLUS' ENTERED AT 18:16:58 ON 20 OCT 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Oct 2004 VOL 141 ISS 17

FILE LAST UPDATED: 19 Oct 2004 (20041019/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1

L2 402 L1

=> s l2 and micro?

2105390 MICRO?

L3 48 L2 AND MICRO?

=> s l3 and particle

621330 PARTICLE

701149 PARTICLES

1052058 PARTICLE

(PARTICLE OR PARTICLES)

L4 5 L3 AND PARTICLE

=> s l3 and diameter

20680 DIAMETER

1897 DIAMETERS

22274 DIAMETER

(DIAMETER OR DIAMETERS)

381322 DIAM

40439 DIAMS

408143 DIAM

(DIAM OR DIAMS)

422933 DIAMETER

(DIAMETER OR DIAM)

L5 0 L3 AND DIAMETER

=> s l2 and micronized

2954 MICRONIZED

10/796,313

L6 2 L2 AND MICRONIZED

=> dup rem 16 14

PROCESSING COMPLETED FOR L6

PROCESSING COMPLETED FOR L4

L7 5 DUP REM L6 L4 (2 DUPLICATES REMOVED)

=> d 17 ibib hitstr abs 1-5

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2004:182593 CAPLUS

DOCUMENT NUMBER: 140:235504

TITLE: Preparation and crystallization of bicalutamide

INVENTOR(S): Dolitzky, Ben-Zion; Reany, Ofer; Shammai, Jenny

PATENT ASSIGNEE(S): Israel

SOURCE: U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S. Ser. No. 170,721.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004044249	A1	20040304	US 2003-606403	20030625
US 2003045741	A1	20030306	US 2002-170721	20020613
US 6737550	B2	20040518		
US 2004059147	A1	20040325	US 2003-668982	20030922
US 6797843	B2	20040928		
US 2004167349	A1	20040826	US 2004-791468	20040301
US 2004176633	A1	20040909	US 2004-796313	20040308
US 2004176638	A1	20040909	US 2004-796822	20040308
PRIORITY APPLN. INFO.:			US 2001-298009P	P 20010613
			US 2002-371069P	P 20020409
			US 2002-170721	A2 20020613

OTHER SOURCE(S): CASREACT 140:235504


IT 90357-06-5P, Bicalutamide

RL: PEP (Physical, engineering or chemical process); PUR (Purification or recovery); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(preparation, micronization and crystallization of bicalutamide)

RN 90357-06-5 CAPLUS

CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



AB Racemic N-[4-cyano-3-trifluoromethylphenyl]-3-[4-fluorophenylsulfonyl]-2-hydroxy-2-methylpropionamide (bicalutamide) was prepared starting from Et pyruvate and Me methacrylate. Thus, 5-amino-2-cyanobenzotrifluoride was treated with DABCO and reacted with deprotonated Et 2-(4-

fluorophenylsulfonyl)-2-hydroxy-2-methylpropionate (prepared from Et pyruvate) to give 40% bicalutamide. **Micronized** particles of bicalutamide can be obtained as pharmaceutical compns. that are useful for its anti-androgen activity (no data). Bicalutamide intermediates were also prepared, including Et 2-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropionate, Me 2,3-epoxy-2-methylpropionate and 2-hydroxy-2-methyl-3-(4-fluorophenylthio)propionic acid. The present invention further discloses the isolation and purification of bicalutamide by various crystallization methods.

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:472643 CAPLUS

DOCUMENT NUMBER: 139:30801

TITLE: Assays and implements for determining and modulating heat shock protein 90 (HSP90) binding activity, and therapeutic use

INVENTOR(S): Kamal, Adeela; Burrows, Francis J.; Zhang, Lin; Boehm, Marcus F.

PATENT ASSIGNEE(S): Conforma Therapeutics Corporation, USA

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050295	A2	20030619	WO 2002-US39993	20021212
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003066005	A2	20030814	WO 2003-US4283	20030210
WO 2003066005	A3	20040610		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2004054624	A1	20040701	WO 2003-US18776	20030612
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,			

10/796,313

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2001-340762P P 20011212
US 2002-355275P P 20020208
US 2002-367055P P 20020322
WO 2002-US39993 A 20021212

OTHER SOURCE(S): CASREACT 139:30801


IT 90357-06-5, Bicalutamide

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(assays and implements for determining and modulating heat shock protein 90
binding activity, and therapeutic use with other agents)

RN 90357-06-5 CAPLUS

CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-
fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



AB Ligand binding assays as applied to HSP90s as receptors or ligands, and reagents useful therefore, are described and claimed, as are methods of assaying for HSP90 modulators and methods of using the resulting products identified thereby. The methodol. of the invention may be used in the treatment and prevention of an HSP90-mediated disease, e.g. cancer. Modulators of the invention include e.g. ansamycins.

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2002:964133 CAPLUS

DOCUMENT NUMBER: 138:24551

TITLE: Preparation of rac-bicalutamide

INVENTOR(S): Dolitzky, Ben-Zion; Reany, Ofer; Shamai, Jenny

PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva
Pharmaceuticals USA, Inc.; Biogal Gyogyszergyar

SOURCE: PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100339	A2	20021219	WO 2002-US18329	20020613
WO 2002100339	A3	20031016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

10/796,313

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1406855 A2 20040414 EP 2002-739801 20020613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:

US 2001-298009P P 20010613
US 2002-371069P P 20020409
WO 2002-US18329 W 20020613

*Priority
docs.*


OTHER SOURCE(S): CASREACT 138:24551

IT 90357-06-5P, Bicalutamide

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of rac-bicalutamide)

RN 90357-06-5 CAPLUS

CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



AB Racemic and optically active N-[4-cyano-3-trifluoromethylphenyl]-3-[4-fluorophenylsulfonyl]-2-hydroxy-2-Me propionamide (bicalutamide) were prepared starting from Et pyruvate and Me methacrylate. Thus, 5-amino-2-cyanobenzotrifluoride was treated with DABCO and reacted with deprotonated ethyl-[2-(4-fluorophenyl sulfone)]-2-hydroxy propionate (prepared from Et pyruvate) to give %40 rac-bicalutamide. **Micronized** particles of rac-bicalutamide can be obtained as pharmaceutical comps. that are useful for its anti-androgen activity (no data). Bicalutamide intermediates were also prepared, including ethyl-[2-(4-fluorophenyl sulfone)]-2-hydroxy propionate, 1,2-epoxy-2-Me propionate and 2-hydroxy-2-methyl-3-(4-fluorophenylthio) propionic acid.

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:637506 CAPLUS

DOCUMENT NUMBER: 137:190729

TITLE: Novel modified-release formulation containing amphiphilic lipids as a hydrophobic matrix former

INVENTOR(S): Juppo, Anne

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064121	A1	20020822	WO 2002-SE228	20020208
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,			

10/796,313


UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1368006 A1 20031210 EP 2002-710645 20020208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
BR 2002006825 A 20040225 BR 2002-6825 20020208
JP 2004518709 T2 20040624 JP 2002-563916 20020208
US 2004067256 A1 20040408 US 2003-467900 20030811
NO 2003003564 A 20031002 NO 2003-3564 20030812
PRIORITY APPLN. INFO.: SE 2001-477 A 20010213
SE 2001-478 A 20010213
WO 2002-SE228 W 20020208

IT 90357-06-5, Bicalutamide

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release multiparticulate solid dispersion formulation
containing amphiphilic lipid matrix)

RN 90357-06-5 CAPLUS

CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-
fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



AB The present invention is directed to a multiparticulate, modified release solid dispersion formulation, comprising a drug substance having a water-solubility of ≤ 8 mg/mL at room temperature, a hydrophobic matrix former which is a water insol., non-swelling amphiphilic lipid, and a hydrophilic matrix former which is a meltable, water-soluble excipient. The weight ratio of

hydrophobic matrix former to hydrophilic matrix former is ≥ 1 , and the **particle** size is < 300 μm . Also a unit dosage of the same, as well as process for the preparation thereof and the use of the formulation and unit dosage are claimed. For example, felodipine (1 g) was dissolved in a melt of 4 g cetanol at 110° and 2 g of Poloxamer 407 was added into the melt. The melted mixture was kept at 110° and atomized at air temperature of 400° and a pressure of 7 bar; the **particles** were collected into a vessel which was kept at temperature -50° , and thereafter dried over night in a vacuum oven at 25° and 2 mbar. The resulted **particles** had a 90% fractile size (90% smaller than) of 77 μm and a roundness of 0.87.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:293419 CAPLUS

DOCUMENT NUMBER: 136:315004


TITLE: Liposomes encapsulating anticancer drugs and the use thereof in the treatment of malignant tumors

INVENTOR(S): Parente Duena, Antonio; Pons Lambiez, Ferran; Fabra Fres, Angels; Polo Trasancos, Maria Dolores; Garces

10/796,313

PATENT ASSIGNEE(S): Garces, Josep; Reig Isart, Francesca
SOURCE: Lipotec, S.A., Spain
PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030397	A1	20020418	WO 2001-ES367	20011003
WO 2002030397	C2	20040513		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
ES 2186484	A1	20030501	ES 2000-2447	20001010
ES 2186484	B1	20040701		
AU 2001091904	A5	20020422	AU 2001-91904	20011003
EP 1325739	A1	20030709	EP 2001-972111	20011003
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001013552	A	20030729	BR 2001-13552	20011003
JP 2004510811	T2	20040408	JP 2002-533840	20011003
PRIORITY APPLN. INFO.:			ES 2000-2447	A 20001010
			WO 2001-ES367	W 20011003
IT 90357-06-5, Bicalutamide				
RL:	PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)			
	(lipopeptide liposomes encapsulating anticancer drugs and the use thereof in the treatment of malignant tumors)			
RN 90357-06-5 CAPLUS				
CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-	(9CI) (CA INDEX NAME)			



AB The invention relates to liposomes encapsulating anticancer drugs and the use thereof in the treatment of malignant tumors. The liposomes are covered by a lipopeptide consisting of three substructures: a lipid fragment, an active oligopeptide and a spacer oligopeptide between the two fragments. Said liposomes can be used in i.v. administration for the treatment of malignant tumors.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/796,313

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

34.16

39.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.50

-3.50

STN INTERNATIONAL LOGOFF AT 18:20:54 ON 20 OCT 2004